Anthera Pharmaceuticals Announces Presentation of Blisibimod Lupus Research at the American Society of Nephrology Annual Meeting
01 nov. 2017 17h00 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) will present new data from the CHABLIS-SC1 Phase 3 clinical study of blisibimod, a novel treatment that...